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progression-free survival. Timing of molecular testing via polymerase chain reac-
tion (PCR) varies. Once patients have achieved and maintained MMR 12 months,
3 panelists would reduce the frequency of cytogenetic testing and 3 would cease
cytogenetic testing. Mutational analysis is not routinely conducted in responding
patients; however, when performed in the second- and third-line settings, muta-
tional analyses are generally conducted once or twice yearly. Healthcare resource
utilization was higher in patients with advanced-phase disease and was 2-3 times
higher in nonresponders than responders. CONCLUSIONS: CML treatment and
monitoring practices may not align with guidelines; furthermore, patient manage-
mentmay differ markedly between treatment settings. Monitoring disease burden
using PCR is expected to become increasingly important with standardization, and
new therapies are anticipated to yield deeper responses.
PCN13
REAL LIFE OUTCOMES IN 2ND LINE ADVANCED OR METASTATIC NON-SMALL
CELL LUNG CANCER (NSCLC): A PILOT STUDY IN FRANCE AND GERMANY
ANALYSING ERLOTINIB VERSUS CHEMOTHERAPY
Vergnenegre A1, Heigener DF2, Bischoff HG3, Chouaid C4, Taylor-Stokes G5, Roughley A5,
Walzer S6
1SIME, Limoges, France, 2Krankenhaus Grosshansdorf, Grosshansdorf, Germany, 3Thoraxklinik
Heidelberg GmbH, Hedelberg, Germany, 4Hôpital Saint Antoine, Paris, France, 5Adelphi Real
World, Macclesfield, Cheshire, UK, 6F. Hoffmann-La Roche Pharmaceuticals AG, Basel,
Switzerland
BACKGROUND: Erlotinib is an EGFR TKI inhibitor used as monotherapy in second-
line NSCLC patients. Clinical studies have demonstrated the survival benefits of
erlotinib, however outcomes from routine clinical practice have not previously
been assessed in Europe. OBJECTIVES: To investigate Time to Progression (TTP)
and thus to assess the feasibility of such studies in a European setting. The primary
comparison was erlotinib versus chemotherapy in second-line NSCLC.METHODS:
Data were drawn from the Adelphi NSCLC Disease Specific Programme, a large
cross-sectional study of consecutively presenting patients in France and Germany
in 2010. Physicians provided retrospective information regarding disease status
and treatment patterns. TTP was defined as time from start of second-line treat-
ment to physician-reported disease progression or two weeks before the start of
third-line therapy. A log rank test was applied to test for differences between the
two comparison groups. Sensitivity analyses on the treatment effect were run on
EGFRmutationwild-type and non-tested patients. RESULTS: 521 patients receiving
second line therapy were included in the analyses, of which 123 were receiving
erlotinib and 398 were receiving other chemotherapy regimens. 60 patients were
EGFR mutated, 150 were EGFR wild type and 311 were not tested. Only 19 erlotinib
and 83 non-erlotinib patients had progressed. The median time to progression for
erlotinib patients was 17 months compared with 9.5 months in the comparison
group. The Hazard ratio relating to the treatment effect (erlotinib versus non-
erlotinib)was 0.63 (95%CI 0.38 to 1.05) p0.07. The results of the sensitivity analysis
on the EGFRmutation wild-type and non-tested patients resulted in a Hazard ratio
of 0.65, p0.13. CONCLUSIONS: The feasibility of using real life oncology data has
been demonstrated. TTP observed for erlotinib and chemotherapy was similar,
independent of mutation status, in second-line NSCLC.
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OBJECTIVES:Docetaxel (D) prednisone (P), mitoxantrone (MTX), estramustine (E)
and sipuleucel-T (S) are authorized in the US for castrate-resistant prostate cancer
(CRPC) treatment. New agents such as abiraterone and zibotentan are being inves-
tigated. This systematic review aims to assess current clinical evidence of treating
metastatic CRPC (mCRPC). METHODS: MEDLINE, Embase, and Cochrane were
searched to March 22, 2010, as were abstracts from ASCO, ASCO GU, AUA, ESMO,
and EAU (2006 – March 2010). RCTs and observational studies (English) were in-
cluded. Endpoints extracted include overall survival (OS), progression-free survival
(PFS), prostate-specific antigen (PSA) response, and adverse events (AEs). RESULTS:
A total of 171 studies (331 publications) were included: prechemotherapy patients
(71 RCTs, 15 observational), postchemotherapy patients (6 RCTs, 71 observational),
and mixed populations (8 RCTs). D, P, and E were most commonly investigated. In
postchemotherapy RCTs, D P custirsen (14.7 mos) and cabazitaxel P (15mos)
exhibited a relatively high OS compared to other regimens. Regimens with D and
MTX showed longer PFS versus other regimens. D regimens were associated with a
high PSA response (40%). In postchemotherapy observational studies, D  bevaci-
zumab showed a relatively high OS (17.5 mos) and PFS (8.9 mos). In prechemo-
therapy RCTs, S (26 mos) and D  P (27 mos) showed a high OS. D  P showed a
favorable PFS (11mos), as did E etoposide (15mos). Overall, PRO, bone pain, and
skeletal-related events were rarely reported in these studies. Nausea, anemia,
diarrhea, neutropenia, and thrombocytopenia were common across trials.
Grade 3/4 AEs were frequently reported with D-based regimens. CONCLUSIONS:
mCRPC remains a clinical challenge. D was frequently investigated. D improved
survival but produced significant AEs. New treatments for D-refractory patients
are needed.
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OBJECTIVES: To assess the coverage of HPV immunizations two years since their
introduction, and to determine factors associated with vaccination. METHODS:
The present research has been conducted in Maccabi Healthcare Services, the sec-
ond largest HMO in Israel. The study population consisted of women aged 8 to 43.
Multivariate analyses were used to determine independent association of various
factorswith vaccination. RESULTS:The study population included 482,748women,
of which 3.8% purchased at least one HPV vaccine dose. HPV vaccine initiation was
strongly associated with socioeconomic level, with chances for immunization be-
ing approximately 35-fold higher in the highest SES index as compared to the
lowest. High proportion of women aged 21-25 were vaccinated, but the rate in
younger girls, who are the target population were much lower. CONCLUSIONS:
HPV immunizations, which are not part of the current Israeli immunization pro-
gram, are purchased mainly by women older than 20 years from high socio-eco-
nomic classes.
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OBJECTIVES: To determine the trends in type of chemotherapy regimens admin-
istered to early stage or metastatic breast cancer patients in daily practice, as this
information is lacking in published literature.METHODS: Newly diagnosed breast
cancer patients in the period 2000-2008 who received chemotherapy were selected
from the Dutch ECR-PHARMO cohort. The ECR (Eindhoven Cancer registry) records
data on all newly diagnosed cancer patients in the Southeastern Netherlands
whereas the PHARMO RLS (PHARMO Record Linkage System) includes data on,
among other things, in- and outpatient drug use. Chemotherapy regimens were
classified based on the received combinations and sequences. Trends in the distri-
bution of adjuvant chemotherapy regimens (for early stage breast cancer) and
palliative chemotherapy regimens (for metastatic breast cancer) were determined
and stratified by Her2/neu status when possible. RESULTS: In this study, 422 pa-
tients diagnosed with early stage breast cancer received adjuvant chemotherapy.
The use of CMF decreased from 90% in 2000 to almost none since 2005. Adminis-
tration of anthracyclines (without taxanes) increased from 4% in 2000 to 94% in
2005, but lowered to 60% in 2008, being replaced by both trastuzumab and taxanes
(with or without anthracyclines). Among the 82 breast cancer patients who re-
ceived palliative chemotherapy at diagnosis or after breast cancer recurrence, the
use of CMF and anthracyclines (without taxanes) decreased (0% and 15% in 2008,
respectively), while the use of taxanes (with or without anthracyclines) increased
(26% in 2008). Trastuzumab was used as palliative chemotherapy from 2003 on-
wards, with 22% of the metastatic breast cancer patients receiving trastuzumab
containing regimens in 2008, and bevacizumab was administered since 2007 with
19% of the patients receiving bevacizumab containing regimens in 2008.
CONCLUSIONS: Key findings on chemotherapeutic treatment for breast cancer
patients from large clinical trials have been incorporated in the Dutch guidelines
resulting in major changes in patient care.
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OBJECTIVES: There is an increase in incidence ofmalignantmelanoma (MM). How-
ever, there is no systematic estimation of prevalence of advanced MM in the US.
The SEER registry does not provide prevalence by tumor stage or data on tumor
recurrence rates. This study takes a public health approach in reporting MM prev-
alence rate and future trend by tumor stage and age. The objective of this study is
to build upon SEER data to inform public health interventions. METHODS: An ex-
cel-based,multi-cohort natural historymodelwas developed. It employed age- and
stage-specific incidence, recurrence, and all-causemortality rates, and the US Cen-
sus data from up-to-date SEER data and literature. The estimations were projected
to 2015. RESULTS: Our model estimated that there were approximately 1.2 million
MM cases (376 per 100,000 people) in the US in 2010. Of which, (24.4%) were in
advanced stages (regional: 169,975 (14.6%); distant: 114,666 (9.8%)). The estimated
prevalence rate of advanced MM in 2010 was 92 per 100,000 people. Among these
advanced cases, 149,148 cases (52.4%) were in the elderly ( 65y). The total cases of
MM of all stages and advanced cases were projected to increase from 2010 to 2015
by 38.4% and 57.9%, respectively. When compared to the latest SEER reported na-
tionalMMprevalence of all stages in 2007 (793,283 cases), our estimate for the same
year was 965,933 cases, or 21.8% higher, due to difference in projection methodol-
ogy. Of these 2007 MM cases, 332,149 (41.9%) and 429,479 (44.5%) were estimated to
be in the elderly. CONCLUSIONS: Prevalence of advanced MM is projected to in-
crease in the next five years. These estimates help enhance public health aware-
ness. An accurate estimation of disease burden is essential in prioritizing health
care resource allocation and in identifying unmet needs fromdisease prevention to
treatment.
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